Lipid nanocarriers and molecular targets for malaria chemotherapy

Curr Drug Targets. 2014 Mar;15(3):292-312. doi: 10.2174/13894501113146660235.

Abstract

Malaria is the most serious tropical disease of humankind and a cause of much debilitation and morbidity throughout the world especially in endemic areas like India and Africa. The development of drug resistance may be due to insufficient drug concentration in presence of high parasite load. In addition, the present pharmaceutical dosage forms are ineffective thereby necessitating the development of novel dosage forms which are effective, safe and affordable to underprivileged population of the developing world. The rapid advancement of nanotechnology has raised the possibility of using lipid nanocarriers that interact within biological environment for treatment of infectious diseases. Thus, lipid based nano-delivery systems offer a platform to formulate old and toxic antimalarial drugs thereby modifying their pharmacokinetic profile, biodistribution and targetability. Further, there is a need to develop new chemotherapy based approaches for inhibiting the parasite-specific metabolic pathways. The present review highlights the advances in lipid nanocarriers and putative molecular targets for antimalarial chemotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antimalarials / therapeutic use*
  • Drug Delivery Systems
  • Drug Therapy
  • Humans
  • Lipids / administration & dosage*
  • Malaria / drug therapy*
  • Metabolic Networks and Pathways / drug effects
  • Molecular Targeted Therapy
  • Nanotechnology / methods*
  • Plasmodium / drug effects

Substances

  • Antimalarials
  • Lipids